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Abstract
SARS Coronavirus 2 (SARS-CoV-2) emerged in late 2019, leading to the Coronavirus Dis-
ease 2019 (COVID-19) pandemic that continues to cause significant global mortality in
human populations. Given its sequence similarity to SARS-CoV, as well as related coronavi-
ruses circulating in bats, SARS-CoV-2 is thought to have originated in Chiroptera species in
China. However, whether the virus spread directly to humans or through an intermediate
host is currently unclear, as is the potential for this virus to infect companion animals, live-
stock, and wildlife that could act as viral reservoirs. Using a combination of surrogate entry
assays and live virus, we demonstrate that, in addition to human angiotensin-converting
enzyme 2 (ACE2), the Spike glycoprotein of SARS-CoV-2 has a broad host tropism for
mammalian ACE2 receptors, despite divergence in the amino acids at the Spike receptor
binding site on these proteins. Of the 22 different hosts we investigated, ACE2 proteins from
dog, cat, and cattle were the most permissive to SARS-CoV-2, while bat and bird ACE2 pro-
teins were the least efficiently used receptors. The absence of a significant tropism for any
of the 3 genetically distinct bat ACE2 proteins we examined indicates that SARS-CoV-2
receptor usage likely shifted during zoonotic transmission from bats into people, possibly in
an intermediate reservoir. Comparison of SARS-CoV-2 receptor usage to the related coro-
naviruses SARS-CoV and RaTG13 identified distinct tropisms, with the 2 human viruses
being more closely aligned. Finally, using bioinformatics, structural data, and targeted muta-
genesis, we identified amino acid residues within the Spike–ACE2 interface, which may
have played a pivotal role in the emergence of SARS-CoV-2 in humans. The apparently
broad tropism of SARS-CoV-2 at the point of viral entry confirms the potential risk of infec-
tion to a wide range of companion animals, livestock, and wildlife.
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Introduction
The β-coronavirus SARS Coronavirus 2 (SARS-CoV-2) emerged in late 2019, causing a large
epidemic of respiratory disease in the Hubei Province of China, centred in the city of Wuhan
[1]. Subsequent international spread has led to an ongoing global pandemic, currently respon-
sible for over 43 million infections and 1,100,000 deaths (as of October 26, 2020, Johns Hop-
kins University statistics; https://coronavirus.jhu.edu/map.html). As for SARS-CoV, which
emerged in China in late 2002, and Middle East Respiratory Syndrome-related Coronavirus
(MERS-CoV), which emerged in Saudi Arabia in 2012, the original animal reservoir of zoo-
notic coronaviruses is thought to be bats [2]. Spillover into humans is suspected or proven to
be facilitated through an intermediate host, e.g., civets for SARS Coronavirus (SARS-CoV) [2]
or camels for MERS-CoV [3]. For SARS-CoV-2, a bat origin is supported by the 2013 identifi-
cation of a related coronavirus RaTG13 from Rhinolophus affinis (intermediate horseshoe bat),
which is 96% identical at the genome level to SARS-CoV-2 [1]. Identifying the animal reservoir
of SARS-CoV-2, and any intermediate hosts via which the virus ultimately spread to humans,
may help to understand how, where, and when this virus spilled over into people. This infor-
mation could be vital in identifying future risk and preventing subsequent outbreaks of both
related and unrelated viruses. Concurrent to this, there is also a need to understand the
broader host tropism of SARS-CoV-2 beyond its established human host, in order to forewarn
or prevent so-called reverse zoonoses, e.g., the infection of livestock or companion animals.
The latter could have serious implications for disease control in humans and consequently
impact on animal health and food security as we seek to control the Coronavirus Disease 2019
(COVID-19) pandemic.
The process of viral transmission is complex and governed by a range of factors that in
combination determines the likelihood of successful infection and onward spread. The first
barrier that viruses must overcome to infect a new host, whether that be typical (of the same
species as the currently infected host) or atypical (a new species), is entry into the host cell.
Entry is governed by 2 opposing variables: the first being efficient virus binding to the host cell
and the second being host-mediated inhibition of this process, e.g., through virus-specific neu-
tralising antibodies. In the case of SARS-CoV-2, it is likely that in late 2019, the entire global
population was immunologically naïve to this virus, although there is debate as to whether pre-
existing immunity to the endemic human-tropic coronaviruses, e.g., OC43 and HKU1, pro-
vides any cross-protective antibodies to help mitigate disease symptoms [4]. To compound
this, the rapid global spread of SARS-CoV-2, combined with emerging molecular data [5,6],
has clearly demonstrated that SARS-CoV-2 is efficient at binding to and entering human cells.
However, how widely this host range or receptor tropism extends and the molecular factors
defining atypical transmission to nonhuman hosts remain the subject of intense investigation.
Coronavirus entry into host cells is initiated by direct protein–protein interactions between
the virally encoded homo-trimeric Spike protein, a class I transmembrane fusion protein
found embedded in the virion envelope, and proteinaceous receptors or sugars on the surface
of host cells [7]. The high molecular similarity of β-coronaviruses allowed the rapid identifica-
tion of angiotensin-converting enzyme 2 (ACE2) as the proteinaceous receptor for SARS-
CoV-2 [8,9], and structural studies characterising Spike and its interactions with ACE2 have
quickly followed [5,6,10,11] and extended recently to include RaTG13 [12]. These studies have
identified a high affinity interaction between the receptor binding domain (RBD) of Spike and
the N-terminal peptidase domain of ACE2, which for SARS-CoV was shown to determine the
potential for cross-species infection and, ultimately, pathogenesis [13].
The availability of ACE2 gene sequences from a range of animal species enables study of the
receptor tropism of β-coronavirus Spike proteins. This can be achieved through computational
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predictions based on ACE2 sequence conservation [14] or, more directly, with functional
experimental investigation [1]. In this paper, we examined whether ACE2 from 22 different
species of livestock, companion animals, and/or wildlife, alongside human ACE2, could sup-
port the entry of SARS-CoV-2, SARS-CoV, and RaTG13. Using 2 distinct assays, we identified
that SARS-CoV-2 has a broad receptor tropism for mammalian ACE2 proteins including
human, hamster, pig, and rabbit. Efficient infection via these ACE2 receptors was subsequently
confirmed using live SARS-CoV-2 virus. Interestingly, the host range of SARS-CoV-2 was sim-
ilar to that of SARS-CoV, yet distinct from its closest genetic relative RaTG13. The genetic
determinants of this receptor tropism were further investigated, and individual amino acids
within the Spike–ACE2 interface were identified as critical to β-coronavirus human tropism.
This research has identified vertebrate species where cell entry is most efficient, allowing prior-
itisation of in vivo challenge studies to assess disease susceptibility. Combining this with
increased surveillance and improved molecular diagnostics could help to prevent future
reverse zoonoses.
Results
The SARS-CoV-2 binding site on ACE2 is highly variable
Recent structural and functional data have shown that SARS-CoV, SARS-CoV-2, and other β-
coronavirus (lineage B clade 1) Spike proteins bind the same domain in ACE2 to initiate viral
entry [5,6,8–10]. We thus hypothesised that SARS-CoV-2 could use the ACE2 receptor to
infect a range of nonhuman, non-bat hosts. To this end, we synthesised expression constructs
for human ACE2 as well as orthologues from 22 other vertebrate species, including 9 compan-
ion animals (dogs, cats, rabbits, guinea pigs, hamsters, horses, rats, ferrets, and chinchilla), 7
livestock species (chickens, cattle, sheep, goats, pigs, turkeys, and buffalo), 4 bat species (horse-
shoe bat, fruit bat, little brown bat, and flying fox bat), and 2 species confirmed or suspected to
be associated with coronavirus outbreaks (civet and pangolin). There is 62% to 99% sequence
identity between these proteins at the amino acid level (76% to 99% when excluding the 2 bird
sequences), and their phylogenetic relationships are largely consistent with vertebrate phylog-
eny, although the guinea pig sequence was more divergent than predicted (Fig 1A). Examining
the conservation of amino acids at the SARS-CoV-2 binding site on the surface of the ACE2
protein revealed a high degree of variation across mammalian taxa (Fig 1B and 1C), suggesting
that SARS-CoV-2 receptor binding may vary between potential hosts. This variation was also
evident when aligning the 23 ACE2 sequences included in our study, which identified a num-
ber of highly variable residues within the overlapping SARS-CoV and SARS-CoV-2 binding
sites, including Q24, D30, K31, H34, L79, and G354 (Fig 1D). Our first step was to ensure effi-
cient and equivalent surface expression of these ACE2 proteins on target cells. To this end,
their N-terminal signal peptides were replaced with a single sequence from the commercially
available pDISPLAY (Thermo Fisher Scientific, United States of America) construct (Fig 1E).
In addition, the ectodomain was fused with an HA-epitope tag to allow the specific detection
of surface expressed protein. Western blot of whole cell lysates together with flow cytometric
analysis of cell surface expression confirmed that in the majority of cases, the 23 ACE2 proteins
were expressed to similar levels, thereby allowing side-by-side comparison of their usage by
SARS-CoV-2 (Figs 1F and 1G and S1). The marked exceptions were flying fox bat and guinea
pig ACE2 where protein expression and cell-surface presentation were barely detectable (Fig
1F and 1G). The cause of this poor expression is unknown, potentially arising due to errors in
the ACE2 sequences available for these species (see Methods; Phylogenetic analysis). Since the
available sequence accuracy for these 2 genes would need to be explored further, these 2 ACE2
proteins were excluded from our subsequent experiments.
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Fig 1. The SARS-CoV-2 binding site on ACE2 is highly variable. (A) A phylogenetic tree of ACE2 proteins assembled using the neighbor-joining method
[51] conducted in MEGA7 (Temple University, USA) [52] with ambiguous positions removed. The tree is drawn to scale, and support was provided with 500
bootstraps. (B) Structure of human ACE2 ectodomain (green) in complex with the RBD of SARS-CoV-2 [10]. (C) Conservation of mammalian ACE2 amino
acid residues, estimated from site-specific evolutionary rates [50], mapped onto the surface of the ACE2 ectodomain [10], and coloured from blue (divergent)
to purple (conserved) and presented in 2 orientations. Inset depicts the SARS-CoV-2 binding region of ACE2 (outlined), with residues that contact the
SARS-CoV-2 RBD highlighted [6]. (D) WebLogo (University of California, Berkeley, USA) [53] plots summarising the amino acid divergence within the
mammalian and bird ACE2 sequences characterised in this study. The single letter amino acid (aa) code is used with the vertical height of the amino acid
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Receptor screening using surrogate entry assays identifies SARS-CoV-2
Spike as a pan-tropic viral attachment protein
To examine the capacity of SARS-CoV-2 to enter cells bearing different ACE2 proteins, we
used 2 related approaches. The first, based on the widely employed pseudotyping of lentiviral
particles with SARS-CoV-2 Spike [9], mimics particle entry. The second approach, based on a
quantitative cell–cell fusion assay, we routinely employ for the morbilliviruses [15], assessing
the capacity of Spike to induce cell–cell fusion following receptor engagement. In both assays,
we used a codon-optimised SARS-CoV-2 Spike expression construct as the fusogen, demon-
strating robust and sensitive detection of either entry or fusion above background (S2A and
S2B Fig). Supportive of our technical approach, replacing the human ACE2 signal peptide
with that found in pDISPLAY had no effect on pseudotype entry or cell–cell fusion, nor did
the addition of the HA-tag (S2A and S2B Fig). In addition, SARS-CoV-2 entry was shown only
with human ACE2, but not with aminopeptidase N (APN) or dipeptidyl peptidase 4 (DPP4),
the β-coronavirus group I and MERS-CoV receptors, respectively (S2 Fig), indicating high
specificity in both assays. Using the classical pseudotype approach, which models particle
engagement with receptors on the surface of target cells, we demonstrated that SARS-CoV-2
Spike has a relatively broad tropism for mammalian ACE2 receptors. Indeed, we observed that
pangolin, dog, cat, horse, sheep, and water buffalo all sustained higher levels of entry than was
seen with an equivalent human ACE2 construct (Fig 2A; left heatmap, first column). In con-
trast, all 3 bat ACE2 proteins we analysed (fruit bat, little brown bat, and horseshoe bat) sus-
tained lower levels of fusion than was seen with human ACE2, as did turkey and chicken
ACE2, the only nonmammalian proteins tested. In accordance with previously published data
on SARS-CoV and SARS-CoV-2 usages of rodent ACE2 [1,16], rat ACE2 did not efficiently
support SARS-CoV-2 particle entry. However, we observed that the ACE2 from hamsters did
support pseudoparticle entry, albeit less efficiently than human ACE2.
In the separate cell–cell fusion assay, which provides both luminescence and fluorescence-
based monitoring of syncytium formation, a similar trend was observed with expression of
chinchilla, cat, pig, sheep, goat, water buffalo, and cattle ACE2 proteins on target cells all yield-
ing higher signals than target cells expressing human ACE2 (Fig 2A; left heatmap, second col-
umn). Similar to the pseudotype assay, the expression of all 3 bat ACE2 proteins resulted in
less cell–cell fusion than that seen with human ACE2. The heatmaps presented in Fig 2A repre-
sent the averaged results from 3 entirely independent pseudotype and cell–cell assay receptor
usage screens (with representative data sets shown in S3 Fig).
Combining the results from all 6 screens demonstrates a significant degree of concordance
between the 2 experimental approaches (Fig 2B). Although the high correlation (Pearson
r = 0.84) was unsurprising, given that both approaches rely on the same Spike–ACE2 engage-
ment, fusogen activation and membrane fusion process (albeit at virus–cell or cell–cell inter-
faces), there were some marked differences in sensitivity. For the pseudotype system, there was
little appreciable evidence for particle entry above background levels with ferret, rat, chicken,
turkey, or horseshoe bat ACE2, compared with either vector control (pDISPLAY) transfected
cells (Fig 2A; bottom row) or ACE2-transfected cells infected with a “no glycoprotein”
representing its prevalence at each position in the polypeptide (aa 18–46, 78–91, 324–358, and 392–394 are indicated). The aa sites bound by SARS-CoV and
SARS-CoV-2 Spike [11] are indicated by red arrows. �SARS-CoV-specific interactions. (E) ACE2 sequences were cloned into the pDISPLAY expression
construct in frame with an N-terminal signal peptide (the murine Ig κ-chain leader sequence) and HA-tag. (F) Expression of individual mammal or bird
ACE2 proteins was confirmed at a whole cell level by western blot. (G) Flow cytometry was performed to examine surface expression of each ACE2 protein
on non-permeabilised cells. For gated cells, the percentage positivity and MFI are plotted. The data underlying this figure may be found in S1 Data and S1
Raw Images. aa, amino acid; ACE2, angiotensin-converting enzyme 2; MFI, mean fluorescence intensity; RBD, receptor binding domain; SARS-CoV, SARS
Coronavirus; SARS-CoV-2, SARS Coronavirus 2.
https://doi.org/10.1371/journal.pbio.3001016.g001
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pseudoparticle control, non-enveloped (NE) (S3 Fig). However, in the cell–cell system, all of
these receptors permitted Spike-mediated fusion, above the background levels seen in pDIS-
PLAY transfected cells (Fig 2A) or in effector cells not expressing SARS-CoV-2 Spike (S3 Fig;
Fig 2. Receptor screening using surrogate entry assays identifies SARS-CoV-2 Spike as a pan-tropic viral attachment protein. (A) A heatmap illustrating
the receptor usage profile of SARS-CoV-2 and SARS-CoV in pseudotype entry and cell–cell fusion assays with various mammalian and bird ACE2s. The data
in each row are normalised to the signal seen for human ACE2 (top), with results representing the mean percentage calculated from 3 separate experiments
performed on different days. A vector-only control (pDISPLAY) was added to demonstrate specificity. Mammalian and bird ACE2s are organised, top to
bottom, based on their phylogenetic relationship (rectangular cladogram, left). The inter-experimental standard error of the mean for the pseudotype and
cell–cell fusion assays ranged from 0.01% to 47.92% (median 10.73%) and 0.12% to 32.97% (median 5.43%), respectively. (B and C) For both SARS-CoV-2
and SARS-CoV, the respective cell–cell and pseudotype assay percentages for each ACE2 protein (relative to human ACE2) were plotted on an XY scatter
graph, the Pearson correlation calculated and a linear line of regression fitted together with 95% confidence intervals. The data underlying this figure may be
found in S1 Data. ACE2, angiotensin-converting enzyme 2; SARS-CoV, SARS Coronavirus; SARS-CoV-2, SARS Coronavirus 2.
https://doi.org/10.1371/journal.pbio.3001016.g002
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no spike), albeit at levels significantly lower than that seen for human ACE2. This suggests that
these receptors, whose structures are clearly not optimal for SARS-CoV-2 entry, are still
bound by the Spike protein. Of note, the entry of SARS-CoV-2 and SARS-CoV is facilitated by
the cellular serine protease transmembrane protease serine 2 (TMPRSS2), which primes the
coronavirus Spike through specific cleavage events [8]. During the optimisation of our ACE2
receptor screening experiments, we also examined how transient expression of TMPRSS2
affects SARS-CoV-2 particle entry and cell–cell fusion. In our pseudoparticle entry experi-
ments, overexpression of TMPRSS2 had a negligible impact on entry when cognate ACE2
receptors were expressed on target cells (S4A Fig; human, dog, cat, pig, and goat). We believe
this is likely due to the saturation of pseudoparticle viral entry, a result of cognate ACE2 over-
expression. Importantly however, receptors, which showed little evidence of supporting parti-
cle entry when expressed on their own, supported much more robust levels of entry when
TMPRSS2 was co-expressed (S4A Fig; turkey and chicken), despite TMPRSS2 protein alone
not supporting entry (S4B Fig). A similar trend was observed in our cell–cell fusion assay. Co-
expression of human ACE2 and TMPRSS2 in target cells or separately trypsin treatment of
Spike expressing effector cells both led to larger syncytia when compared with ACE2 alone,
likely the result of direct activation of a greater percentage of the SARS-CoV-2 Spike found at
the cell–cell interface (S4C Fig). However, TMPRSS2 co-expression significantly enhanced the
use of non-cognate receptors (S4D Fig; fruit bat, ferret, turkey, and chicken), when compared
with ACE2 or ACE2 and trypsin treatment. Since we were specifically interested in assessing
nonhuman ACE2 interactions with SARS-CoV-2 Spike, we therefore did not include overex-
pressed TMPRSS2 in any of our host range receptor screening experiments (Fig 2).
To facilitate comparison with existing data for SARS-CoV, we also performed similar recep-
tor screening experiments with SARS-CoV pseudotype and cell–cell assays (Fig 2A and 2C,
right heatmap and S2 and S3 Figs). While the receptor usage profile of SARS-CoV correlates
significantly with SARS-CoV-2, both in terms of pseudotype entry (S5A Fig; r = 0.85) and
cell–cell fusion (S5B Fig; r = 0.81), there were interesting divergences. Although there was a
similar restriction for bird and bat ACE2 proteins, our side-by-side comparison identified
instances of varying restriction, with ferret, fruit bat, and civet ACE2 appearing to be preferen-
tially used by SARS-CoV (Figs 2A and S5B). In summary, using 2 distinct technical approaches
that monitor Spike-mediated receptor usage in a biologically relevant context, we provide evi-
dence that SARS-CoV-2 has a broad tropism for mammalian ACE2s. These assays demon-
strate correlation between ACE2 protein sequence and fusion by SARS-CoV or SARS-CoV-2
Spike protein, plus evidence of a low affinity of SARS-CoV Spike proteins for bird or rat ACE2
and varying levels of bat ACE2 utilisation.
A cognate ACE2 receptor is required for SARS-CoV-2 infection
High-throughput and robust surrogate assays for SARS-CoV-2 viral entry only serve to model
this process and can never completely replace live virus experiments. To this end, and in order
to examine the permissiveness of nonhuman cell lines in our cell culture collection to SARS-
CoV-2, we experimentally infected a range of animal cells including those established from
birds, canids, rodents, ruminants, and primates (see S1 Table for details on species and cell
type) with SARS-CoV-2 isolated from a patient in the United Kingdom (SARS-CoV-2
England-2/2020). Infection at a low multiplicity of infection (MOI) (0.001) failed to generate
infectious virus in any of the cells tested, apart from 2 monkey cell lines (Vero E6 and Marc
145), in line with primate cells being used widely to propagate SARS-CoV-2 [17] (Fig 3A).
Repeat infections at a higher MOI (1) in a subset of these cells (PK15, RK13, DF-1, and BHK-
21) established evidence for a very low level of virus production only in the porcine cell line
PLOS BIOLOGY SARS-CoV-2 host range
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PK15 (Fig 3B). Subsequent quantitative PCR (qPCR) analysis of ACE2 mRNA levels in the
whole panel of cell lines, assayed using a novel panel of species-specific ACE2 primers, identi-
fied only 2 cell lines (Vero E6 and Marc 145) with cycle threshold (Ct) values less than 25 (Fig
3A), providing a strong correlative link between ACE2 receptor expression and successful
virus infection.
We next sought to correlate the receptor usage results from our surrogate entry assays (Fig
2) with live virus infections. A baby hamster kidney cell line (BHK-21), which we established
Fig 3. A cognate ACE2 receptor is required for SARS-CoV-2 infection. (A) Various cell lines derived from birds,
dogs, rabbits, rodents, pigs, ruminants, and primates were experimentally infected with SARS-CoV-2 at a MOI of
0.001. At 72 h postinfection, the supernatants from cells were harvested and titred by TCID-50. For each cell line, RNA
from uninfected cells was also extracted, and RT-qPCR was performed to detect ACE2 mRNA, with the value above
each line indicating the cycle when PCR positivity was achieved (Ct). (B) Four of the same cell lines were infected
again, this time at high MOI (1). (C) BHK-21 hamster cells were transiently transfected with ACE2 expression
constructs (or a vector control [pDISPLAY]) before being infected with SARS-CoV-2 at high MOI (1). �p< 0.05
Student t test, compared with pDISPLAY. For all high MOI experiments, supernatant samples were harvested at 48 hpi
for titration by TCID-50. The DL for the TCID-50 is indicated. In all experiments, the initial inoculum used for
infection was titred, and infections were performed in duplicate, with error bars denoting standard deviation from the
mean. The data underlying this figure may be found in S1 Data. ACE2, angiotensin-converting enzyme 2; BHK-21,
baby hamster kidney 21; Ct, cycle threshold; DL, detection limit; MOI, multiplicity of infection; RT-qPCR, reverse
transcription quantitative PCR; SARS-CoV-2, SARS Coronavirus 2; TCID50, 50% tissue culture infective dose.
https://doi.org/10.1371/journal.pbio.3001016.g003
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as refractory to SARS-CoV-2 infection (Fig 3A and 3B), was transfected with vector alone
(pDISPLAY) or a restricted panel of ACE2 constructs (hamster, human, horseshoe bat, rabbit,
pig, and chicken) representing the spectrum of receptor usage (Fig 2A). Concurrent to the
infections, the expression of ACE2 in equivalently transfected cells was confirmed by western
blot, flow cytometry, and SARS-CoV-2 pseudotype infections (S6A–S6C Fig). Of note, for the
live virus infections the high MOI (1), the inoculum was removed after 1 h with the cells thor-
oughly washed prior to incubation at 37˚C. Accordingly, in the BHK-21 cells transfected with
carrier plasmid, we saw very little evidence for virus infection and/or virus production, con-
firming that these cells do not natively support SARS-CoV-2 infection (Fig 3C). For the recep-
tors where we had previously seen high levels of cell–cell fusion (hamster, pig, and rabbit), we
observed robust viral replication (Fig 3C). Surprisingly, the 2 receptors included because of
their “poor” usage by SARS-CoV-2 Spike (horseshoe bat and chicken ACE2, Fig 2A) were still
able to support viral replication, albeit to a lower level (<5% of human ACE2 levels). Of note,
regardless of the ACE2 species expressed, we saw very little evidence of cytopathic effect in the
infected BHK-21 cells (S6D Fig), despite the release of infectious virus into the supernatant
(S6E Fig). Lastly, focusing on the unexpected observation that chicken ACE2 permitted
SARS-CoV-2 entry into cells, we investigated whether chicken embryonic fibroblast cells (DF-
1) overexpressing chicken or human ACE2 could support viral replication. While western blot
and flow cytometry demonstrated successful ACE2 overexpression (S7A and S7B Fig), we did
not see any evidence of viral replication in these cells (S7C Fig). Since human ACE2 is effi-
ciently used by SARS-CoV-2 Spike, we suspect that this is because of cell-specific deficiencies
elsewhere in the virion entry pathway and/or a postentry block to viral replication in chicken
cells. Interestingly, analysis of publicly available transcriptomic data from DF-1 cells [18] iden-
tified no detectable TMPRSS2 expression (S7D Fig). However, furin and cathepsin B mRNAs
were both present. In summary, SARS-CoV-2 is able to use a range of nonhuman ACE2 recep-
tors to enter cells. Furthermore, when a cognate ACE2 is provided, the virus can replicate effi-
ciently in the normally refractory hamster cell line BHK-21.
Amino acid substitutions within SARS-CoV-2 Spike RBD may have
contributed to zoonotic emergence
The identification, isolation, and sequencing of SARS-CoV-2 progenitors in animal reservoirs
or intermediate hosts could provide important information to explain how this virus emerged
in human populations. However, as discussed previously, the most closely related virus strain
currently available to researchers is RaTG13, isolated in R. affinis bats in 2013. A recent struc-
ture for RaTG13 Spike [12] allowed us to directly compare the RBDs of SARS-CoV-2 and
RaTG13, identifying a high degree of structural conservation (Fig 4A). However, concurrent
sequence analysis identified a number of variable residues within the RBD, which interact
directly with ACE2 (Fig 4A, inset panel). Building on the hypothesis that the progenitor of
SARS-CoV-2 was RaTG13-like, we next developed pseudotype and cell–cell fusion assays for
RaTG13 Spike (S8A–S8C Fig) to examine the biological properties of this protein. Interest-
ingly, RaTG13 Spike did not pseudotype as efficiently as SARS-CoV-2 or SARS-CoV, although
it did retain significant fusogenicity in the cell–cell assay (Fig 4B). Screening with our panel of
mammalian and bird ACE2 constructs also identified a phenotypically distinct pattern of
receptor usage (Figs 4B and S8D and S8E) (Pearson r correlation RaTG13 versus SARS-CoV-
2 = 0.573 for pseudotype entry and 0.510 for SARS-CoV, S8F and S8G Fig). Surprisingly,
RaTG13 receptor usage of human ACE2 was still higher than that of horseshoe bat ACE2,
although the human ACE2 values were significantly lower than those observed for SARS-
CoV-2 and SARS-CoV (Fig 4B, blue data points). Importantly, the differing receptor usage
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Fig 4. Amino acid substitutions within SARS-CoV-2 Spike RBD may have contributed to zoonotic emergence. (A) Comparison of the RBD structures of
SARS-CoV-2 and RaTG13 Spike proteins [6,12] identified a high degree of structural similarity. Nevertheless, a number of amino acid changes between
RaTG13 and SARS-CoV-2 were identified at residues interacting directly with ACE2 (according to [6]). SARS-CoV-2 N439, which does not interact directly
with ACE2, was included because of its functional stabilisation role in the 498–505 loop, its previous identification within the SARS-CoV Spike RBD–ACE2
interface [19], and the N439K substitution present in RaTG13. (B) An XY scatter plot demonstrating the receptor usage profile of RaTG13 Spike in
pseudotype (X) and cell–cell fusion assays (Y). Each point represents the mean signal seen from 3 experiments performed on separate days, with the human
ACE2 highlighted in blue. Human ACE2 utilisation by SARS-CoV-2 and SARS-CoV Spike is also plotted for reference. In this graph, values are not
normalised to human ACE2 since RaTG13 is, to our knowledge, not a human-tropic virus. (C and D) Specific amino acids within the RBDs of SARS-CoV-2
and RaTG13 Spike, which directly interact with ACE2 yet vary between these 2 sequences, were mutated to generate chimaeric SARS-CoV-2-RaTG13 Spike
proteins. The cell–cell fusion activity of individual point mutants, as well as a full chimaera containing all 8 mutations (chimaera), was then examined using
human ACE2 expressing target cells with activity normalised to the fusion seen with the wildtype (WT) viral glycoprotein of (C) SARS-CoV-2 or (D)
RaTG13. The data points shown are the mean cell–cell fusion results seen in 3 completely independent experiments (green, increased relative activity; red,
decreased relative activity). �p< 0.05 Student t test, compared with WT. (E) Expression of the same mutants was analysed by western blot targeting the flag
tag fused to these Spike proteins (S, full-length Spike; S1/S2, cleaved variant). Results are representative of protein expression experiments performed in
duplicate, with a GAPDH loading control also shown. The data underlying this figure may be found in S1 Data and S1 Raw Images. ACE2, angiotensin-
converting enzyme 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RBD, receptor binding domain; RLU, relative light units; SARS-CoV, SARS
Coronavirus; SARS-CoV-2, SARS Coronavirus 2; WT, wildtype.
https://doi.org/10.1371/journal.pbio.3001016.g004
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pattern of RaTG13 Spike, which contrasts with its high genetic similarity to SARS-CoV-2
Spike (98% at the amino acid level), indicated that amino acid variation within the RBD of this
protein (Fig 4A) may play a deterministic role in host range. To identify which residues play a
direct role in human ACE2 tropism, we generated a panel of RaT13 and SARS-CoV-2 Spike
chimaeras, further examining our hypothesis that SARS-CoV-2 progenitors were RaTG13-
like. Variable amino acids within the RBD were substituted with their corresponding residue
in SARS-CoV-2 or RaTG13 Spike and the activity of these mutants assessed in a cell–cell
fusion assay with human ACE2 (Fig 4C and 4D). Substitution of SARS-CoV-2 RBD residues
proximal to the ACE2-binding surface [19] with those found in RaTG13 Spike was almost uni-
versally detrimental to human ACE2 receptor usage (Fig 4C), while an opposite trend was seen
for RaTG13 (Fig 4D), aside from the substitutions at Spike positions 439 and 498, which were
inhibitory in both contexts. In particular, the F449Y, L486F, Y493Q, D501N, and H505Y
mutations to RaTG13 Spike markedly increased human ACE2 receptor usage. In contrast, the
complete SARS-CoV-2/RaTG13 chimaeras containing all substitutions within ACE2-binding
region of the RBD (Fig 4C and 4D; chimaera) were nonfunctional and had altered electropho-
retic mobility in western blots (Fig 4E) suggesting that the deleterious mutations (K439N or
Y498Q) have a dominant effect in inhibiting ACE2 utilisation, perhaps by impeding correct
folding of the mutated RaTG13 and SARS-CoV-2 proteins, as well as potentially the cleavage
of SARS-CoV-2 Spike into S1 and S2 (Fig 4E; left panel). If our hypothesis that SARS-CoV-2
arose from a RaTG13-like progenitor is correct, then mutations at these residues may have
played an important role in the emergence of SARS-CoV-2 in the human population. Indeed,
a similar pattern of mutations was identified for SARS-CoV during its emergence from its
intermediate civet host [13,20], highlighting a potentially conserved mechanism for β-corona-
virus adaptation to the human ACE2 receptor. Of note, the described mutants were con-
structed only in RaTG13 Spike expression plasmids, and assays were only performed in
surrogate receptor usage assays, an approach we have previously used to safely interrogate the
zoonotic potential of other viruses [15].
Discussion
Recognising animals at risk of infection and/or identifying the original or intermediate hosts
responsible for the SARS-CoV-2 pandemic are important goals for ongoing COVID-19
research. In addition, there is a requirement to develop appropriate animal models for infec-
tion that, if possible, recapitulate the hallmarks of disease seen in people. Importantly, high-
resolution structures of human ACE2 in complex with the Spike RBD [5,6,10,11] can help us
to understand the genetic determinants of SARS-CoV-2 host range and pathogenesis. In par-
ticular, differences in receptor usage between closely related host species or viruses provides an
opportunity to pinpoint amino acid substitutions at the interaction interface that inhibit Spike
protein binding and fusion, and ultimately determine host range.
One example of closely related ACE2 sequences differing in their utilisation by SARS-CoV-
2 Spike comes from the comparison of rat and hamster ACE2. Although a number of animal
models have been investigated for SARS-CoV-2, including nonhuman primates, ferrets, and
cats [21,22], the use of small animals, in particular rodents, has proved more challenging as
murine and rat ACE2 support lower levels of β-coronavirus entry [1,16]. For SARS-CoV, this
problem was circumvented with the development of transgenic mice expressing human ACE2
[23] or mouse-adapted SARS-CoV [24,25], research that has recently been extended to SARS--
CoV-2 [26]. Consistent with previously published data on SARS-CoV rodent ACE2 interac-
tions, we showed that rat ACE2 does not support SARS-CoV-2-mediated fusion (Fig 2A). The
hamster cell lines we used in our study (BHK-21 and Chinese hamster ovary (CHO)) are likely
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refractory to infection simply because they express low levels of ACE2 mRNA (Fig 3A, qPCR
data). However, our finding that hamster ACE2 allows the entry of SARS-CoV-2 (Fig 2A) indi-
cates this animal is a suitable model for infection, consistent with recent in vivo studies dem-
onstrating experimental infection of these animals [27]. Comparison of the hamster and rat
sequences (Fig 5A) identified multiple substitutions at the RBD interaction interface that
might explain this variable receptor tropism (listed as hamster to rat): Q24K, T27S, D30N,
L79I, Y83F, and K353H. Except for L79I, which is similarly substituted in pangolin and pig
ACE2, all of these substitutions are likely to reduce Spike RBD binding. Q24K and Y83F sub-
stitutions would both result in the loss of hydrogen bonds with the side chain of SARS-CoV-2
RBD residue N487 (Fig 5B). The T27S substitution would remove the threonine side chain
methyl group that sits in a hydrophobic pocket formed by the side chains of RBD residues
F456, Y473, A475, and Y489, and substitution of residue D30 (which is acidic in all ACE2 pro-
teins efficiently utilised by SARS-CoV-2 Spike) to asparagine would remove the salt bridge
formed with K417 of the RBD (Fig 5B). Furthermore, the K353H substitution would remove
hydrogen bond interactions with the side chain of RBD Q498 and the backbone carbonyl oxy-
gen of RBD G496, and neither of these could be formed by the shorter histidine side chain (Fig
5B). This K353H substitution is particularly noteworthy because mouse ACE2, which is also
unable to efficiently bind SARS-CoV-2 Spike [1], also has a histidine at residue 353. However,
introduction of the substitutions Q498Y and P499T in the Spike protein is sufficient to confer
upon SARS-CoV-2 the ability to replicate in mice [26]. Introducing the larger tyrosine side
chain at position 498 would likely restore a hydrogen bond with mouse ACE2 H353 and could
facilitate hydrophobic interactions with the side chain of ACE2 Y41. Thus, multiple substitu-
tions are predicted to inhibit Spike binding to rat ACE2 when compared with the closely
related hamster protein, with K353H being of particular relevance (Fig 5B). Interestingly,
along with Mus musculus [26], a similar ACE2 sequence-dependent susceptibility to SARS-
CoV-2 has now been demonstrated for deer mice [28].
Another example of different receptor usage between closely related species can be seen
with bat ACE2 (Figs 2A and 5A). The apparent lack of tropism for bat ACE2 proteins we
observed was surprising as there is previous evidence of SARS-CoV-2 infection of bat ACE2
expressing cells in vitro [1], and in vitro binding experiments suggest that the SARS-CoV-2
RBD binds bat ACE2 with high affinity [29]. Since the exact origin of SARS-CoV-2 is currently
unknown, but widely accepted to be a Chiroptera species, we included ACE2 proteins from a
broad range of bats in our study. While none of these bat ACE2s supported SARS-CoV-2
fusion to the same levels as humans, there were dramatic differences in the ability of SARS-
CoV-2 Spike to utilise the ACE2 from horseshoe bats versus fruit bats and little brown bats
(Fig 2A). As discussed earlier, the closest known relative of SARS-CoV-2, RaTG13, was iso-
lated from intermediate horseshoe bat (R. affinis). Unfortunately, the ACE2 sequence from
this species was not available for use in our study; however, we did include an ACE2 from the
closely related least horseshoe bat (Rhinolophus pusillus). Although this protein supported the
lowest levels of fusion of any bat ACE2 tested in our study, it still supported a low level of
SARS-CoV-2 replication with live virus (Fig 3C). As in rat ACE2, horseshoe bat and fruit bat
ACE2 have a lysine residue at position 24 that would disrupt hydrogen bonding to N487 of the
SARS-CoV-2 RBD and introduce a charge (Fig 5A and 5B). Little brown bats have the hydro-
phobic residue leucine at this position, which could not form the hydrogen bond to N487 but
which is present in ACE2 from several species that support high levels of fusion, suggesting
that the loss of the hydrogen bond is less deleterious to Spike protein binding than introduc-
tion of the lysine positive charge. Fruit bats conserve a T27, whereas little brown bats have the
bulkier isoleucine residue and horseshoe bats have a bulky charged lysine residue in this posi-
tion, both of which are likely to clash with the F456-Y473-A475-Y489 hydrophobic pocket of
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the RBD, with the lysine substitution likely to be more deleterious due to the introduction of
the positive charge. Like rats, horseshoe bat N30 would be unable to form a salt bridge with
RBD K417. Substitution of Q42 with glutamate in little brown bat may be detrimental to Spike
binding, as it would disrupt the hydrogen bond to the backbone carbonyl oxygen of RBD
Fig 5. Substitutions at the interface between SARS-CoV-2 RBD and mammalian ACE2 proteins impact receptor
utilisation. (A) Residues of mammalian ACE2 sequences used in this study that are predicted to interact with the RBD
SARS-CoV and SARS-CoV-2, based on the structures of human ACE2 in complex with SARS-CoV [19] and
SARS-CoV-2 [6]. Differences between closely related species that may impact RBD binding are highlighted. (B)
Interface between human ACE2 (green) and SARS-CoV-2 RBD (yellow). Insets 1 to 5 show molecular interactions
discussed in the main text. Bonds that may be disrupted are shown as grey lines, with bond distances in grey text, and
hydrophobic interactions that may be disrupted are marked with asterisks. ACE2, angiotensin-converting enzyme 2;
RBD, receptor binding domain; SARS-CoV, SARS Coronavirus; SARS-CoV-2, SARS Coronavirus 2.
https://doi.org/10.1371/journal.pbio.3001016.g005
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residue G446. The other substitutions between bat ACE2 proteins and other mammals are
likely to be benign. Little brown bats, horseshoe bats, pangolins, and horses all share a serine as
ACE2 residue 34, suggesting that serine in this position does not abolish Spike binding, and it
is likely that the threonine at this position (fruit bat ACE2) would likewise be tolerated. Simi-
larly, the Y41H substitution present in little brown bat ACE2 is also present in horse ACE2,
suggesting that it does not prevent binding. Therefore, all bat ACE2 proteins have substitutions
that impair SARS-CoV-2 Spike binding to different degrees, but it seems likely that the E30N
substitution (shared only by rat ACE2) or introduction of a charged lysine residue at position
27 (unique to horseshoe bats) are the most likely causes of the severely impaired binding of
SARS-CoV-2 Spike to horseshoe bat ACE2.
Interestingly, a similarly “poor” tropism for bat ACE2 was also reported for SARS-CoV fol-
lowing its emergence in 2002 [30]. Specifically, coronaviruses closely related to SARS-CoV
that were isolated directly from bats were shown to inefficiently use either human or civet
ACE2 [30]. This is consistent with large shifts in receptor usage occurring during coronavirus
species jumps, either directly into humans or more likely via intermediate reservoirs. During
the SARS-CoV epidemic, where civets were identified as the intermediate reservoir of infec-
tion, a shifting pattern of increasing and decreasing ACE2 usage was observed in individual
isolates of SARS-CoV taken from civets and humans (although they shared approximately
99% similarity to each other), providing evidence for adaptation to individual host receptors
[13,20] with a particular focus on differential adaptation to human ACE2 residues K31 (T31 in
civets) and K353. Interestingly, correlation analysis of SARS-CoV and SARS-CoV-2 pseudo-
type entries highlighted civet ACE2 as being strongly favoured by SARS-CoV, perhaps a legacy
of this period of adaptation in an intermediate host (S5A Fig). Although data analysis of this
type between related viruses might represent a mechanism for identifying intermediate reser-
voirs, similar outliers that favoured SARS-CoV-2 entry were not evident in our study. As dis-
cussed above, the lack of similarly closely related SARS-CoV-2 isolates from this outbreak’s
origin in Hubei makes detailed interpretation of this virus’s adaptation to human ACE2 diffi-
cult at this time. However, to address this gap in our understanding, we performed detailed
analysis of the closest relative of SARS-CoV-2, RaTG13. Strikingly, RaTG13 was shown to
have a distinct receptor usage pattern from SARS-CoV-2, with SARS-CoV-2 and SARS-CoV
being significantly more related (S8F and S8G Fig; SARS-CoV-2 Pearson correlation r = 0.57
[RatG13] versus 0.83 [SARS-CoV]). This is despite SARS-CoV-2 and RaTG13 Spike being
98% identical at the amino acid level, with SARS-CoV-2 and SARS-CoV sharing only 77%
identity. Our mutational analysis of the SARS-CoV-2 and RaTG13 RBD identified a number
of residues that are important in conferring human ACE2 tropism to the Spike protein (Fig 4C
and 4D). Structural studies of SARS-CoV-2 [6], and more recently RaTG13 [12], help to shed
light on the interactions underpinning these phenotypic changes (Fig 6). An F449Y substitu-
tion in RaTG13 Spike would allow hydrogen bonds to be formed with the D38 and Q42 side
chains of ACE2, with the loss of the tyrosine hydroxyl group explaining the small loss of func-
tion for the Y449F mutation in SARS-CoV-2 (Figs 4C and 4D and 6). The drop in SARS-CoV-
2 fusion activity of the F486L mutant (Fig 4C) is likely due to reduced ACE2 affinity arising
from weakened interactions between the shorter leucine side chain and a hydrophobic pocket
on ACE2 formed by L79, M82, and Y83 side chains and the M82-Y83 peptide plane (Fig 6).
The converse is seen with the RaG13 L486F mutant (Fig 4D), suggesting that an extended
hydrophobic interaction at this locus is important in conferring tropism to the human ACE2
receptor. The reduced ACE2 utilisation by Q493Y-substituted SARS-CoV-2 Spike (Fig 4C) is
likely due to the loss of a hydrogen bond with ACE2 E35 and steric clashes between the bulky
tyrosine side chain and the side chain of ACE2 K31 (Fig 6), with the reciprocal change in
RaTG13 (Y493Q) giving rise to increased fusion (Fig 4D). The Y505H substitution in
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SARS-CoV-2 Spike also reduced human ACE2 receptor usage, with a concordant increase in
RaTG13 activity when the reciprocal H505Y substitution was introduced (Fig 4C and 4D).
This can potentially be explained by the terminal hydroxyl group of Y505, which makes a
hydrogen bond with ACE2 E37, and by the aromatic region of the tyrosine side chain that
forms hydrophobic interactions with the alkyl region of the K353 side chain (Fig 6). The
RaTG13 H505 side chain is too short to sustain this hydrogen bond and would make less
extensive hydrophobic interactions; thus, the loss (or gain) of this hydrogen bond may
decrease (or increase) human ACE2 binding. One site where reciprocal substitutions between
SARS-CoV-2 and RaTG13 do not give rise to concomitant loss or gain of receptor utilisation is
residue 439, as both the SARS-CoV-2 N439K and RaTG13 K439N mutants exhibit reduced
fusion (Fig 4C and 4D). Residue 439 does not interact directly with ACE2, but in SARS-CoV-
2, the N439 side chain forms hydrogen bonds with the side chain of SARS-CoV-2 S443 and
with the backbone carbonyl oxygen of SARS-CoV-2 P499 (Fig 6). The N439K substitution
may modestly alter the conformation and increase the flexibility of the 437–448 and 498–505
loops in SARS-CoV-2, both of which interact with ACE2, leading to modestly decreased recep-
tor utilisation (Fig 4C). In RaTG13, residue 443 is an alanine and would thus be unable to
form a hydrogen bond with the asparagine side chain introduced by the K439N substitution
(Fig 6), potentially leading to a structural rearrangement of the RaTG13 437–448 loop that is
deleterious to ACE2 binding (Fig 4D). It is notable that several of the SARS-CoV-2 residues
that are important for human ACE2 receptor utilisation bind in close proximity to the 2 hot-
spots for human ACE2 adaptation (K31 and K353) that were identified previously for SARS-
CoV (Fig 6, [13]; see also discussion above). Although researchers do not have access to
SARS-CoV-2 viruses, or their progenitors, from wildlife or intermediate hosts, our data
Fig 6. Amino acid variation in SARS-CoV-2 and RaTG13 RBD impacts human ACE2 receptor utilisation. Structure
of RaTG13 RBD (orange) [12] superposed onto the structure of human ACE2 (green) in complex with the SARS-CoV-2
RBD (yellow) [10]. Selected RBD residues that promote association with ACE2 are highlighted, as are the ACE2
“hotspot” residues K31 and K353 [13]. Insets 1 to 5 show molecular interactions discussed in the main text. Bonds that
may be disrupted are shown as grey lines, with bond distances in grey text, and hydrophobic interactions that may be
disrupted or potential steric clashes are marked with asterisks. ACE2, angiotensin-converting enzyme 2; RBD, receptor
binding domain; SARS-CoV-2, SARS Coronavirus 2.
https://doi.org/10.1371/journal.pbio.3001016.g006
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highlight that β-coronavirus adaptation to human ACE2 might follow a conserved mechanism.
The high correlation between SARS-CoV and SARS-CoV-2 host range, despite their genetic
divergence, also indicates zoonotic β-coronaviruses may have a conserved and identifiable pat-
tern of receptor usage. This technique may prove useful for determining the zoonotic potential
of other emerging viruses in the future.
In the process of finalising this manuscript, related studies examining the receptor usage of
various nonhuman ACE2s were published or released as preprints [31–33]. While these studies
did not perform specific examination of cell–cell fusion, there is a strong correlation between
their findings and ours, namely, the broad tropism of SARS-CoV-2 Spike, albeit with specific
examples of restriction in rodent [33], bat [32], and bird [31] species. Our findings are supported
by the results of experimental SARS-CoV-2 infections, which showed that cats [22,34], hamsters
[27], and fruit bats [34] are susceptible to infection, while chickens are not [22]. Elsewhere, evi-
dence for the broad host tropism of SARS-CoV-2 includes the successful establishment of infec-
tion models in rhesus macaques, cynomolgus macaques, and African green monkeys [35–37].
However, certain animals where we demonstrated efficient ACE2 receptor usage, e.g., pigs and
dogs (Fig 2A), appear less susceptible to experimental challenge [22,34]. It should be noted that
particle entry represents only the first step in zoonotic spillover with multiple virus–host interac-
tions combining to define virus host range and pathogenesis. It may be that the intracellular envi-
ronment of specific hosts, e.g., pigs, cannot sustain SARS-CoV-2 infection, either through the
absence of an important virus–host interaction or the presence of effective mechanisms of innate
immune restriction. In this case, SARS-CoV-2 may enter cells efficiently but fail to replicate to sig-
nificant levels to support onward transmission, bring about clinical signs, or induce immunopath-
ological sequelae. In our experiments, the chicken DF-1 cell line was refractory to infection, even
when a cognate ACE2 (human) was overexpressed in these cells. This may be due to an absence
of TMPRSS2 in DF-1s (S7D Fig), although it is currently unclear whether this protease is abso-
lutely required for SARS-CoV-2 entry since alternative pathways for Spike processing have been
identified [38]. The inefficient replication of SARS-CoV-2 in chickens and eggs [22,34,39] indi-
cates that multiple restrictions to efficient viral replication may exist in chicken cells. That being
said, for some animals such as mice [26], it is now clear that inefficient ACE2 receptor usage is
the primary barrier to infection. In summary, although the potential for SARS-CoV-2 to spread
by reverse zoonosis appears real, and there is evidence for community-based infections in mink,
tigers, cats, and dogs [40–42], the epidemiological significance of these infections remains to be
determined. More thorough investigation, including heightened virus surveillance and detailed
experimental challenge studies, are required to ascertain whether livestock and companion ani-
mals could act as reservoirs for this virus. From a molecular perspective, differences in receptor
usage between host and virus are likely the result of amino acid variation within the Spike RBD–
ACE2 interface. Indeed, our mutational analysis of SARS-CoV-2 and RaTG13 Spike confirmed
that changes within this region have a significant impact on human ACE2 interactions, changes
which are implicated in the emergence of SARS-CoV-2 in the human population.
Methods
Cell lines
Cell lines representing a broad range of animal species were used to determine the host range/
tropism of SARS-CoV-2 (S1 Table) (Cell Culture Central Services Unit, The Pirbright Insti-
tute, UK). Cells were maintained in complete medium supplemented with either 10% horse or
bovine viral diarrhea virus (BVDV) and foot and mouth disease virus (FMDV)-negative foetal
bovine serum (FBS) (Gibco, Thermo Fisher Scientific, USA), 1% nonessential amino acids, 1
mM sodium pyruvate solution (Sigma-Aldrich, Germany), 2 mM L-glutamine (Sigma-
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Aldrich), and 1% penicillin/streptomycin, 10,000 U/mL (Life Technologies, Thermo Fisher
Scientific, USA). Additional supplements and cell culture medium for each cell line are sum-
marised in S1 Table. All cells were incubated at 37˚C in a humidified atmosphere of 5% CO2.
Cells used for entry studies or fusion assays: HEK293T cells stably expressing a split Renilla
luciferase-green fluorescent protein (GFP) plasmid (rLuc-GFP 1–7) and BHK-21 cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM)-10%: DMEM (Sigma-Aldrich)
supplemented with 10% FBS (Life Science Production, UK), 1% 100 mM sodium pyruvate
(Sigma-Aldrich), 1% 200 mM L-glutamine (Sigma-Aldrich), and 1% penicillin/streptomycin,
10,000 U/mL (Life Technologies). Stable cell lines were generated, as described previously,
using a lentiviral transduction system under 1 μg/mL puromycin (Gibco) selection [43,44].
Viruses and virus titre quantification
SARS-CoV-2 England-2/2020 was isolated from a patient in the UK, and a passage 1 stock was
grown and titred in Vero E6 cells by Public Health England (PHE) (kindly provided to The
Pirbright Institute by Prof. Miles Carroll). A master stock of virus was passaged to P2 in Vero
E6 at a MOI of 0.001 in DMEM/2% FBS and used for all virus assays, following a freeze–thaw
cycle at −80˚C. Stocks were titred by plaque assay on Vero E6 cells using a 1× minimum essen-
tial media (MEM)/0.8% Avicel/2% FBS overlay, fixed using formaldehyde and stained using
0.1% Toluidine blue. All infections were performed in the Advisory Committee on Dangerous
Pathogens (ACDP) hazard group 3 (HG3) facilities by trained personnel.
Plasmids
Codon-optimised ACE2-expressing plasmids from a range of animal species were synthesised
and cloned into pDISPLAY (BioBasic, Canada) (S2 Table). Codon-optimised SARS-CoV,
SARS-CoV-2, and RaTG13 Spike sequences were synthesised and cloned into pcDNA3.1+
(BioBasic) (S3 Table).
Infections
Initial screen: Cells listed in S1 Table were seeded at a density of 1 × 105 cells/well in a 24-well
plate (Nunc, Thermo Fisher Scientific, USA) and, 24 h later, infected with SARS-CoV-2
England-2/2020. Briefly, media was removed, and the cells washed once with complete
DMEM supplemented with 2% FBS. Cells were then infected at MOI 0.001 and incubated at
37˚C for 1 h. Following this, the inoculum was removed, and cells were washed twice with
PBS, complemented with cell maintenance media and incubated for 72 h at 37˚C. Supernatant
was collected at 72 h postinfection and frozen at −80˚C until required. Cells were fixed with
formaldehyde for 30 min and then stained with 0.1% Toluidine blue (Sigma-Aldrich).
Receptor usage screen: BHK-21 and DF-1 cells were plated at 1 × 105 cells/well in 24-well
plates (Nunc). The following day, cells were transfected with 500 ng of a subset of ACE2
expression constructs (human, hamster, rabbit, pig, chicken, and horseshoe bat) or mock
transfected with an empty vector (pDISPLAY) in OptiMEM (Gibco) using TransIT-X2 trans-
fection reagent (Mirus Bio, USA) according to the manufacturer’s recommendations. Follow-
ing this, cells were infected at MOI 1 as described above, and supernatants were collected at 72
h postinfection and frozen at −80˚C until required.
SARS-CoV-2 and SARS-CoV pseudoparticle infections
Pseudoparticle generation: Lentiviral-based pseudoparticles were generated in HEK293T pro-
ducer cells and seeded in 6-well plates at 7.5 × 105/well 1 day prior to transfecting with the
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following plasmids: 600 ng p8.91 (encoding for HIV-1 gag-pol), 600 ng CSFLW (lentivirus
backbone expressing a firefly luciferase reporter gene), and 500 ng of SARS-CoV-2 Spike,
SARS-CoV Spike or RaTG13 Spike in OptiMEM (Gibco) (S3 Table) with 10 μL polyethylenei-
mine (PEI), 1 μg/mL (Sigma) transfection reagent. No glycoprotein controls (NE) were also set
up using empty plasmid vectors (500 ng pcDNA3.1), and all transfected cells were incubated at
37˚C, 5% CO2. The following day, the transfection mix was replaced with DMEM-10% and
pooled harvests of supernatants containing SARS-CoV-2 pseudoparticles (SARS-CoV-2 pps),
SARS-CoV pseudoparticles (SARS-CoV pps), and RaTG13 pseudoparticles (RaTG13 pps)
were taken at 48 and 72 h post-transfection, centrifuged at 1,300 × g for 10 min at 4˚C to
remove cellular debris, aliquoted and stored at −80˚C. For the initial optimisation of pseudo-
particle activity, 3 conditions were tested: (1) ACE2 expression only: HEK293T target cells
transfected with 500 ng of a human ACE2 expression plasmid (Addgene, USA) and were
seeded at 2 × 104 in 100 μL DMEM-10% in a white-bottomed 96-well plate (Corning, USA) 1
day prior to infection; (2) Spike activation with TMPRSS2: HEK293T target cells were trans-
fected with 25 ng TMPRSS2 alongside human ACE2 as above; (3) Spike activation by trypsin
treatment: viral pseudoparticles were treated with 2.5 mg/mL trypsin for 1 h at 37˚C before
addition to target cells overexpressing human ACE2. SARS-CoV-2 pps, SARS-CoV pps, and
RaTG13 pps, along with their respective NE controls were titrated 10-fold on target cells and
incubated for 72 h at 37˚C, 5% CO2. To quantify firefly luciferase, media was replaced with
50 μL Bright-Glo substrate (Promega, USA), diluted 1:2 with serum-free, phenol red-free
DMEM, incubated in the dark for 2 min and read on a Glomax Multi+ Detection System
(Promega).
Receptor usage screens: BHK-21 cells were seeded in 48-well plates at 5 × 104/well in
DMEM-10% 1 day prior to transfection with 500 ng of different species, ACE2-expressing
constructs or empty vector (pDISPLAY) (S2 Table) in OptiMEM and TransIT-X2 (Mirus Bio)
transfection reagent according to the manufacturer’s recommendations. The next day, cells
were infected with SARS-CoV-2 pp/SARS-CoV pp equivalent to 106 to 107 relative light units
(RLU), or their respective NE controls at the same dilution and incubated for 48 h at 37˚C, 5%
CO2. To quantify firefly luciferase, media was replaced with 100 μL Bright-Glo substrate (Pro-
mega) and diluted 1:2 with serum-free, phenol red-free DMEM. Cells were resuspended in the
substrate, and 50 μL was transferred to a white-bottomed plate in duplicate. The plate was
incubated in the dark for 2 min and then read on a Glomax Multi+ Detection System (Pro-
mega) as above. Comma-separated values (CSV) files were exported onto a universal serial bus
(USB) flash drive for analysis. Biological replicates were performed 3 times.
Cell–cell fusion assays
HEK293T rLuc-GFP 1–7 [45] effector cells were transfected in OptiMEM (Gibco) using Tran-
sit-X2 transfection reagent (Mirus), as per the manufacturer’s recommendations, with SARS-
CoV-2 (1,000 ng), SARS-CoV (1,000 ng), RaTG13 (1,000 ng) (S3 Table), or SARS-CoV-2 and
RaTG13 mutants (S4 Table) alongside mock-transfection with empty plasmid vector
(pcDNA3.1+). BHK-21 target cells were co-transfected with 500 ng of different ACE2-expres-
sing constructs (S2 Table) and 250 ng of rLuc-GFP 8–11 plasmid. In the initial fusion assay
optimisation stage, protease activation was tested in 3 different conditions:(1) overexpression
of ACE2-expresssing constructs only in target cells; (2) co-transfection of 25 ng of human
TMPRSS2 in target cells; or (3) effector cells were washed twice with PBS and incubated with
3 μg/mL of Tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich)
for 30 min at 37˚C before resuspending in phenol red-free DMEM-10%. For the subsequent
receptor usage screens, trypsin treatment was used for Spike activation. Target cells were
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washed once with PBS and harvested with 2 mM EDTA in PBS before coculture with effector
cells at a ratio of 1:1 in white 96-well plates to a final density of 4 × 104 cells/well in phenol red-
free DMEM-10%. Quantification of cell–cell fusion was measured based on Renilla luciferase
activity, 24 h later by adding 1 μM of Coelenterazine-H (Promega) at 1:400 dilution in PBS.
The plate was incubated in the dark for 2 min and then read on a Glomax Multi+ Detection
System (Promega) as above. CSV files were exported onto a USB flash drive for analysis. GFP
fluorescence images were captured every 2 h for 24 h using an Incucyte S3 real-time imager
(Essen Bioscience, Ann Arbor, Michigan, USA). Cells were maintained under cell culture con-
ditions as described above. Assays were set up with 3 or more biological replicates for each
condition, with each experiment performed 3 times.
Western blotting
BHK-21 cells were transfected using Transit-X2 transfection reagent (Mirus Bio), as per the
manufacturer’s instructions with 500 ng of different ACE2-expressing constructs (S2 Table) or
mock-transfected with empty plasmid vector (pDISPLAY). HEK293T cells stably expressing
rLuc-GFP 1–7 were transfected with wild-type SARS-CoV-2 or RaTG13 Spike plasmids or
mutants with amino acid substitutions (S4 Table). All protein samples were generated using
2× Laemmli buffer (Bio-Rad, USA) and reduced at 95˚C for 5 min 48 h post-transfection. Sam-
ples were resolved on 7.5% acrylamide gels by SDS-PAGE, using semidry transfer onto nitro-
cellulose membrane. Blots were probed with mouse anti-human influenza hemagglutinin tag
(HA) primary antibody (Miltenyi Biotech, Germany) for ACE2-transfected cells at 1:1,000 or
with rat anti-FLAG primary antibody (BioLegend, USA) for Spike transfected cells at 1:1,000
in PBS-Tween 20 (PBS-T, 0.1%) with 5% (w/v) milk powder overnight at 4˚C. Blots were
washed in PBS-T and incubated with anti-mouse secondary antibody conjugated with horse-
radish peroxidase (Cell Signalling, USA) at 1:1,000 in PBS-T for 1 h at room temperature.
Membranes were exposed to Clarity Western ECL substrate (Bio-Rad Laboratories) according
to the manufacturer’s guidelines and exposed to autoradiographic film.
Flow cytometry
BHK-21 cells were transfected using Transit-X2 transfection reagent (Mirus Bio), as per the
manufacturer’s instructions with 500 ng of each ACE2-expressing construct (S2 Table) or
mock-transfected with empty plasmid vector (pDISPLAY) for 48 h. Cells were resuspended in
cold PBS and washed in cold stain buffer (PBS with 1% BSA (Sigma-Aldrich), 0.01% NaN3 and
protease inhibitors (Thermo Fisher Scientific, USA)). Cells were stained with anti-HA Phyco-
erythrin (PE)-conjugated antibody (Miltenyi Biotech) at 1:50 dilution for 1 × 106 cells for 30
min on ice, washed twice with stain buffer, and fixed in 2% paraformaldehyde for 20 min on
ice. Fixed cells were resuspended in PBS before being analysed using the MACSQuant Ana-
lyzer 10 (Miltenyi Biotech), and the percentage of PE-positive cells was calculated by compari-
son with unstained and stained mock-transfected samples. Positive cells were gated as
represented in S1 Fig, and the same gating strategy was applied in all experiments.
RNA extraction and ACE2 qPCR quantification
Total cellular RNA was extracted from cell lines in S1 Table using a QIAGEN RNeasy RNA
extraction kit (Qiagen, Germany), and mRNA was then detected with SYBR-Green–based
qPCR (New England Biolabs, NEB, USA), using a standard curve for quantification on a
QuantStudio 3 (Thermo Fisher Scientific, USA) thermocycler. Luna Universal qPCR Master
Mix (NEB) was used to quantify mRNA levels for each cell line. RNA was first transcribed
using SuperScript II Reverse Transcriptase (Thermo Fisher Scientific), with oligo dT primers
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and 50 ng of input RNA in each reaction. All the reactions were carried out following the man-
ufacturer’s instructions and in technical duplicate, with the melt curves analysed for quality
control purposes. Conserved cross-species ACE2 primers used for each cell line are found in
S5 Table.
Structural analysis
Molecular images were generated with an open-source build of PyMOL (Schrödinger, USA)
using the crystal structure of SARS-CoV-2 RBD in complex with human ACE2 (protein data
bank (PDB) ID 6M0J) [10] that had been further refined by Dr Tristan Croll, University of
Cambridge, (https://twitter.com/CrollTristan/status/1240617555510919168) or the cryo-elec-
tron microscopy (EM) structure of RaTG13 Spike [12] superposed onto the SARS-CoV-2 RBD
plus ACE2 complex using the secondary structure mapping (SSM) tool in the Crystallographic
Object-Oriented Toolkit (COOT) software [46]. To analyse the conservation of mammalian
ACE2 receptor sequences, representative sequences were identified via a position-specific iter-
ative (PSI)–BLAST [47] search of the UniRef90 database [48] and filtering for the class Mam-
malia (taxid: 40674). The selected sequences were aligned using Multiple Alignment using Fast
Fourier Transform (MAFFT) [49], and evolutionary conservation of amino acids was mapped
onto the ACE2 structure using ConSurf software [50], implementing a Bayesian framework to
estimate the evolutionary rate of each amino acid in the sequence where slowly evolving resi-
dues are conserved and fast-evolving residues are divergent.
Phylogenetic analysis
ACE2 amino acid sequences were translated from predicted mRNA sequences or protein
sequences (S2 Table). The predicted guinea pig mRNA sequence was more divergent than
expected and contained a premature stop codon. For the purposes of this research, 5 single
nucleotides were added, based on the most closely related sequence (chinchilla), to allow a
full-length mature protein to be synthesised. It is not clear if the guinea pig has a functional
ACE2, or if the quality of the genomic data is very low, but overall confidence in this sequence
is low. The other divergent sequence was turkey as the 30 end was not homologous with other
vertebrate ACE2 receptors. This appeared to be a mis-annotation in the genome as the 30 end
showed very high identity to the collectrin gene. The missing 30 of the gene was found in the
raw genome data and assembled with the 50 region to make a full ACE2 sequence. Twenty-
three nucleotide base pairs were missing between these regions; these were taken from chicken
as the most closely related sequence. Phylogenetic analysis of the final dataset was inferred
using the neighbor-joining method [51] conducted in MEGA7 [52] with ambiguous positions
removed. The tree is drawn to scale, and support was provided with 500 bootstraps.
Data handling and statistical analysis
GraphPad Prism v8.2.1 (GraphPad Software, USA) was used for graphical and statistical analy-
sis of data sets. Flow cytometry data was analysed using FlowJo software v10.6.2 (Becton, Dick-
inson & Company, USA).
Supporting information
S1 Fig. Gating strategy for flow cytometry analysis of ACE2-expressing constructs. BHK-
21 cells were transfected with a panel of species-specific ACE2-expressing constructs (see S2
Table). Cells were surface-stained with anti-HA PE-conjugated antibody. Live and singlet
BHK-21 were gated as PE-positive, relative to mock-transfected cells (top panel).
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Representative datasets are shown for human, goat, and guinea pig ACE2 surface staining
(bottom panel). ACE2, angiotensin-converting enzyme 2; BHK-21, baby hamster kidney;
FSC-A, forward scatter area; HA, human influenza hemagglutinin tag; PE, Phycoerythrin.
(TIF)
S2 Fig. Establishment of SARS-CoV-2 and SARS-CoV entry assays. (A–D) Pseudotype and
cell–cell fusion assays were established for SARS-CoV-2 (A and B) and SARS-CoV (C and D)
using multiple internal controls. For the pseudotype assays NE lentiviral particles were gener-
ated, i.e., vector plasmid in place of a viral glycoprotein, to examine background levels of pseu-
doparticle entry. For the cell–cell fusion assay, mock-transfected effector cells were used (No
Spike) to examine background levels of cell–cell fusion. In all subsequent experiments, “NE”
and “No Spike” controls were compared against SARS-CoV-2 pseudoparticles or SARS-CoV-
2 Spike-expressing effector cells (see S3 Fig). To validate our pDISPLAY approach, cells were
transfected with expression constructs for full-length untagged hACE2 (FL) or a human ACE2
where the signal peptide was replaced with the murine Ig κ-chain leader sequence (hACE2)
and the protein was tagged with the HA-epitope tag. In both instances, the corresponding vec-
tor controls, pcDNA3.1 and pDISPLAY, were separately transfected for comparison. The spec-
ificity of the SARS-CoV-2 and SARS-CoV assays were further confirmed by comparing
hACE2-mediated fusion to human aminopeptidase N (hAPN) or dipeptidyl peptidase 4
(hDPP4) fusion, the coronavirus group I and MERS-CoV receptors, respectively. Lastly, in all
assays, target cells representing un-transfected cells (mock) were also included. For pseudotype
and cell–cell fusion assays, luciferase assays were performed in duplicate and triplicate, respec-
tively, with the error bars denoting standard deviation. The data underlying this figure may be
found in S1 Data. ACE2, angiotensin-converting enzyme 2; HA, human influenza hemaggluti-
nin tag; hACE2, human ACE2; hAPN, human aminopeptidase N; hDPP4, human dipeptidyl
peptidase 4; NE, non-enveloped; SARS-CoV, SARS Coronavirus; SARS-CoV-2, SARS Corona-
virus 2.
(TIF)
S3 Fig. SARS-CoV-2 and SARS-CoV receptor usage screening. As per S2 Fig NE and No
Spike controls were included in all assays, as well as a vector-only control (pDISPLAY). For
pseudotype and cell–cell fusion assays, luciferase assays were performed in duplicate and tripli-
cate, respectively, with the error bars denoting standard deviation. Representative data sets
from individual experiments are shown; however, the heatmaps and XY correlative plots in
Figs 2 and S5 summarise the results from 3 independent experiments performed on separate
days. The data underlying this figure may be found in S1 Data. ACE2, angiotensin-converting
enzyme 2; NE, non-enveloped; RLU, relative light units; SARS-CoV, SARS Coronavirus;
SARS-CoV-2, SARS Coronavirus 2.
(TIF)
S4 Fig. TMPRSS2 protease overexpression masks Spike-ACE2 receptor usage restrictions.
(A) Overexpression of human TMPRSS2 in target cells expressing various host ACE2 proteins
has a negligible impact on SARS-CoV-2 pseudotype entry when a cognate ACE2 is present
(human, dog, cat, pig, or goat); however, it disproportionately enhances entry with non-cog-
nate ACE proteins (turkey and chicken), compared with ACE2 expression alone. Experiments
were performed in biological triplicate and the mean RLU plotted, together with error bars
denoting standard deviation. (B) Expression of TMPRSS2 alone does not support SARS-CoV-
2 entry pseudotypes. NE HIV1 pseudotypes. (C) Trypsin treatment of effector cells or
TMPRSS2 overexpression in the context of ACE2 leads to larger syncytia in SARS-CoV-2 cell–
cell fusion assays. Trypsin treatment also increases SARS-CoV syncytium size, but TMPRSS2
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expression observably reduces syncytia number. (D) Cell–cell fusion assay signals are higher
when TMPRSS2 is co-expressed in target cells, including in target cells expressing non-cognate
ACE2 proteins, e.g., turkey and chicken. Results represent the raw RLU signals from 3 inde-
pendent experiments with the mean signal plotted and error bars denoting standard deviation.
The data underlying this figure may be found in S1 Data. ACE2, angiotensin-converting
enzyme 2; RLU, relative light units; SARS-CoV, SARS Coronavirus; SARS-CoV-2, SARS Coro-
navirus 2; TMPRSS2, transmembrane protease serine 2.
(TIF)
S5 Fig. Correlating SARS-CoV-2 and SARS-CoV pseudotype and cell–cell fusion receptor
usage. The receptor usage data for SARS-CoV-2 and SARS-CoV was examined by separately
comparing the pseudotype (A) or cell–cell fusion (B) assay results on XY scatter plots. Each
point represents the mean activity calculated from 3 independent experiments. The Pearson
correlation was calculated, and a linear line of regression fitted together with 95% confidence
intervals. All values are plotted relative to the entry or cell–cell fusion recorded for human
ACE2 (blue circles). The data underlying this Figure may be found in S1 Data. ACE2, angio-
tensin-converting enzyme 2; SARS-CoV, SARS Coronavirus; SARS-CoV-2, SARS Coronavirus
2.
(TIF)
S6 Fig. Experimental infection of cell lines overexpressing vertebrate ACE2 proteins. (A)
SARS-CoV-2 pseudotype entry was assayed in BHK-21 transfected cells overexpressing ACE2
from the indicated species. Pseudotype infections were performed in triplicate, and the mean
value was plotted on a heatmap following normalisation to human ACE2. Similarly, trans-
fected target cells were lysed, and the ACE2 expression was analysed by western blot (B) or
flow cytometry (C). (D) In parallel, BHK-21 cells were transfected with various ACE2-expres-
sing constructs and infected with SARS-CoV-2 at an MOI of 1. Cells were fixed and stained at
48 hpi. (E) Prior to fixation, the supernatants from infected BHK-21 cells were removed for
quantification of released virus by TCID-50. Representative images of these titrations, per-
formed on Vero E6 cells, are shown (vector-only control [pDISPLAY] as well as human and
chicken ACE2). The data underlying this figure may be found in S1 Data and S1 Raw Images.
ACE2, angiotensin-converting enzyme 2; BHK-21, baby hamster kidney; MOI, multiplicity of
infection; SARS-CoV-2, SARS Coronavirus 2; TCID-50, 50% tissue culture infective dose.
(TIF)
S7 Fig. Infection of chicken embryo fibroblast DF-1 cell with SARS-CoV-2. ACE2 expres-
sion in transfected DF-1 cells (as indicated) was analysed by flow cytometry (A) or western
blot (B). For the flow cytometry, the MFI is shown for chicken and human ACE2-expressing
cells (3264 and 9521 cells, respectively). For the controls, the total MFI of the HA labelling is
shown as a small number of cells (<10) in the positive gate skewed the data. (C) Similarly,
transfected DF-1 cells were infected with SARS-CoV-2 at an MOI of 1, in biological triplicate.
Supernatant samples were harvested at 48 hpi for titration by TCID-50. The detection limit for
the TCID-50 (DL) is indicated. (D) The mRNA expression levels of 3 proteases relevant for
SARS-CoV-2 entry, Furin, Cathepsin B, and TMPRSS2, were evaluated in DF-1 cells by analy-
sis of the publicly available gene expression database series GSE138648 ([18], dataset and
methodology (GSM4114984) available at GEO; https://www.ncbi.nlm.nih.gov/geo/). Samples
from both uninfected [Control] and ILTV DF-1 cells (4 biological replicates [Rep0] per condi-
tion) were examined and FPKM were calculated. The data underlying this figure may be
found in S1 Data and S1 Raw Images. ACE2, angiotensin-converting enzyme 2; DF-1, chicken
embryonic fibroblast cell line; DL, detection limit, FPKM, fragments per kilobase of exon per
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million reads mapped; HA, human influenza hemagglutinin tag; ILTV, infectious laryngotra-
cheitis virus-infected; MFI, mean fluorescent intensity; MOI, multiplicity of infection; SARS-
CoV-2, SARS Coronavirus 2; TCID-50, 50% tissue culture infective dose; TMPRSS2, trans-
membrane protease serine 2.
(TIF)
S8 Fig. RaTG13 receptor screening. (A–C) Pseudotype (A) and cell–cell fusion assays (B and
C) were established for RaTG13 as described for SARS-CoV-2 and SARS-CoV (see S2 Fig). (D
and E) Receptor screening experiments were performed as described for SARS-CoV-2 and
SARS-CoV (see S4 Fig). A representative data set is shown from a RaTG13 pseudotype and
cell–cell fusion screen, with each screen eventually being performed in triplicate. (F) An XYZ
scatter plot examining the receptor usage pattern of SARS-CoV-2 (SARS2; x), SARS-CoV
(SARS1; z), and RaTG13 (y) Spike pseudotypes. The mean RLU data from 3 independent
experiments is plotted with the human ACE2 value highlighted in red. (G) A Pearson correla-
tion matrix for SARS-CoV-2, SARS-CoV, and RaTG13. The same raw RLU receptor usage val-
ues plotted in F were used for these calculations, with pDISPLAY values removed prior to
calculation. The data underlying this figure may be found in S1 Data. ACE2, angiotensin-con-
verting enzyme 2; RLU, relative light units; SARS-CoV, SARS Coronavirus; SARS-CoV-2,
SARS Coronavirus 2.
(TIF)
S1 Table. Cell lines utilised in this study to quantify ACE2 mRNA levels and to assess virus
permissibility.
(DOCX)
S2 Table. Codon-optimised ACE2-expression plasmids used in this study for receptor
usage screens.
(DOCX)
S3 Table. β-coronavirus glycoproteins used in this study for receptor usage screens.
(DOCX)
S4 Table. SARS-CoV-2 and RaTG13 glycoproteins with amino acid mutations in the RBD
used in this study to generate chimaeras.
(DOCX)
S5 Table. qPCR primer sets used in this study to quantify ACE2 mRNA levels.
(DOCX)
S1 Data. Underlying primary data gathered in this study.
(XLSX)
S1 Raw Images. Unedited western blot data in this study.
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